公开(公告)号：US20210310020A1

公开(公告)日：2021-10-07

申请号：US17216169

申请日：2021-03-29

Applicant: CELL&BRAIN CO., LTD.

Inventor： Hae Young Suh ,  Sung Soo Kim ,  Seung Wan Yoo ,  Young Don Lee

IPC: C12N15/85 ,  A61K35/28 ,  A61K35/30 ,  C12N5/0775 ,  C12N15/86

Abstract: The present invention relates to an adult stem cell line introduced with an HGF gene and a neurogenic transcription factor gene of a bHLH family, a preparation method of the adult stem cell line, and a method for treating neurological diseases comprising the step of transplanting the adult stem cell line to a subject having neurological diseases. The adult stem cells according to the present invention, which are introduced with an HGF gene and a neurogenic transcription factor gene of a bHLH family, can be used to treat chronic impairment caused by cell death following stroke. Thus, the adult stem cells can be developed as a novel therapeutic agent or widely used in clinical trial and research for cell replacement therapy and gene therapy that are applicable to neurological diseases including Parkinson's disease, Alzheimer disease, and spinal cord injury as well as stroke.

公开(公告)号：US20240360417A1

公开(公告)日：2024-10-31

申请号：US18631774

申请日：2024-04-10

Applicant: Cell&Brain Co., Ltd

Inventor： Hae Young SUH ,  Sung Soo KIM ,  Da Young CHANG ,  Jin Hwa JUNG ,  Young Don LEE ,  Woo Sup HWANG ,  Jin Sung PARK ,  Su Jung LEE

IPC: C12N5/0775 ,  A61K31/4188 ,  A61K31/4745 ,  A61K31/506 ,  A61K31/513 ,  A61K31/675 ,  A61K31/704 ,  A61K33/243 ,  A61K33/244 ,  A61K35/12 ,  A61K35/28 ,  A61K45/06

CPC classification number: C12N5/0665 ,  A61K31/4188 ,  A61K31/4745 ,  A61K31/506 ,  A61K31/513 ,  A61K31/675 ,  A61K31/704 ,  A61K33/243 ,  A61K33/244 ,  A61K35/12 ,  A61K35/28 ,  A61K45/06 ,  C12N5/0663 ,  C12N2501/73 ,  C12N2510/00 ,  C12N2523/00

Abstract: The present disclosure relates to a method for preparing cells for cancer treatment and a kit for cancer treatment comprising cells prepared by the method. The preparation method of the present disclosure can provide F cells, which, in spite of having no difference in the proliferative capacity compared with mesenchymal stem cells expressing cytosine deaminase that are harvested and used immediately after the culture, exhibit a very excellent tumor suppressive effect through the treatment together with 5-FC and induce a remarkable synergistic effect exceeding an effect from combinative treatment with an existing anticancer drug in cases of a combinative treatment with another anticancer drug. Therefore, the present disclosure can be utilized for a kit for cancer treatment comprising such F cells, and thus can be favorably used to maximize the effect of existing cancer treatments.

公开(公告)号：US20240331802A1

公开(公告)日：2024-10-03

申请号：US18251138

申请日：2021-08-27

Applicant: CELL&BRAIN CO., LTD.

Inventor： Hae Young SUH ,  Au Jin KIM ,  Da Young CHANG ,  Sung Soo KIM ,  Sang Ho KIM

IPC: G16B30/00

CPC classification number: G16B30/00

Abstract: A gene insertion location analysis system for a stem cell therapeutic agent having a specific gene inserted therein comprises: a basic information management unit for managing information essential for operating a gene insertion location analysis system for a stem cell therapeutic agent having a specific gene inserted therein; a gene insertion location analysis unit for managing information for the gene insertion location analysis system; and a DB management unit for managing a DB generated or referred by the basic information management unit and gene insertion location analysis unit.